Early Treatment with Poly(ADP-Ribose) Polymerase-1 Inhibitor (JPI-289) Reduces Infarct Volume and Improves Long-Term Behavior in an Animal Model of Ischemic Stroke
- 405 Downloads
In patients with stroke and neurodegenerative diseases, overactivation of poly(ADP-ribose) polymerase-1 (PARP-1) causes harmful effects by inducing apoptosis, necrosis, neuroinflammation, and immune dysregulation. The current study investigated the neuroprotective effect of a novel PARP-1 inhibitor, JPI-289, in an animal model of ischemic stroke. A transient middle cerebral artery occlusion (tMCAO, 2 h) model was used to determine the therapeutic effect and the most effective dose and time window of administration of JPI-289. We also investigated the long-term outcomes of treatment with JPI-289 by diffusion-weighted imaging (DWI) and fluid-attenuated inversion recovery (FLAIR) MRI and by measuring neurological function at 24 h, 7 days, and 28 days after MCAO. The most effective dose and time window of administration of JPI-289 was 10 mg/kg administered 2 h after MCAO with reperfusion. Twenty-four hours after MCAO, infarct volume was reduced by 53% and the number of apoptotic cells was reduced by 56% compared with control. JPI-289 also reduced infarct volume by 16% in the permanent MCAO model. In an MRI-based study, initial infarct volume, as measured using DWI, was similar in the control and JPI-289-treated groups. However, infarct volume and brain swelling were significantly reduced in the group treated with JPI-289 (2 h) at 24 h and 7 days after MCAO. Neurological functions also improved in the group treated with JPI-289 (2 h) until 28 days after MCAO. Inhibition of PARP-1 has neuroprotective effects (reduction of infarct volume and brain swelling) in both tMCAO and pMCAO models of ischemic stroke.
KeywordsIschemic stroke PARP-1 JPI-289 Neuroprotection
This study was funded by grant of the Korea Drug Development Fund (KDDF-201410-08) and the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (A100453) for the clinical development of JPI-289.
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
All national and institutional guidelines for the care and use of animals were followed.
- 1.Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, Ezzati M, Shibuya K et al (2012) Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380(9859):2197–2223. https://doi.org/10.1016/S0140-6736(12)61689-4 CrossRefPubMedGoogle Scholar
- 2.Wardlaw JM, Murray V, Berge E, del Zoppo G, Sandercock P, Lindley RL, Cohen G (2012) Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet 379(9834):2364–2372. https://doi.org/10.1016/S0140-6736(12)60738-7 CrossRefPubMedPubMedCentralGoogle Scholar
- 10.Kim Y, Kim YS, Noh MY, Lee H, Joe B, Kim HY, Kim J, Kim SH et al (2017) Neuroprotective effects of a novel poly(ADP-ribose) polymerase-1 inhibitor, JPI-289, in hypoxic rat cortical neurons. Clin Exp Pharmacol Physiol 44(6):671–679. https://doi.org/10.1111/1440-1681.12757 CrossRefPubMedGoogle Scholar
- 12.Egi Y, Matsuura S, Maruyama T, Fujio M, Yuki S, Akira T (2011) Neuroprotective effects of a novel water-soluble poly(ADP-ribose) polymerase-1 inhibitor, MP-124, in in vitro and in vivo models of cerebral ischemia. Brain Res 1389:169–176. https://doi.org/10.1016/j.brainres.2011.03.031 CrossRefPubMedGoogle Scholar
- 13.Haddad M, Rhinn H, Bloquel C, Coqueran B, Szabo C, Plotkine M, Scherman D, Margaill I (2006) Anti-inflammatory effects of PJ34, a poly(ADP-ribose) polymerase inhibitor, in transient focal cerebral ischemia in mice. Br J Pharmacol 149(1):23–30. https://doi.org/10.1038/sj.bjp.0706837 CrossRefPubMedPubMedCentralGoogle Scholar
- 16.Rom S, Zuluaga-Ramirez V, Dykstra H, Reichenbach NL, Ramirez SH, Persidsky Y (2015) Poly(ADP-ribose) polymerase-1 inhibition in brain endothelium protects the blood-brain barrier under physiologic and neuroinflammatory conditions. J Cereb Blood Flow Metab 35(1):28–36. https://doi.org/10.1038/jcbfm.2014.167 CrossRefPubMedGoogle Scholar
- 18.Teng F, Beray-Berthat V, Coqueran B, Lesbats C, Kuntz M, Palmier B, Garraud M, Bedfert C et al (2013) Prevention of rt-PA induced blood-brain barrier component degradation by the poly(ADP-ribose)polymerase inhibitor PJ34 after ischemic stroke in mice. Exp Neurol 248:416–428. https://doi.org/10.1016/j.expneurol.2013.07.007 CrossRefPubMedGoogle Scholar
- 21.Kim YS, Yoo A, Son JW, Kim HY, Lee YJ, Hwang S, Lee KY, Lee YJ et al (2017) Early activation of phosphatidylinositol 3-kinase after ischemic stroke reduces infarct volume and improves long-term behavior. Mol Neurobiol 54(7):5375–5384. https://doi.org/10.1007/s12035-016-0063-4 CrossRefPubMedGoogle Scholar
- 22.Chen TY, Goyagi T, Toung TJ, Kirsch JR, Hurn PD, Koehler RC, Bhardwaj A (2004) Prolonged opportunity for ischemic neuroprotection with selective kappa-opioid receptor agonist in rats. Stroke 35(5):1180–1185. https://doi.org/10.1161/01.STR.0000125011.93188.c6 CrossRefPubMedGoogle Scholar
- 23.Zhao X, Liu SJ, Zhang J, Strong R, Aronowski J, Grotta JC (2005) Combining insulin-like growth factor derivatives plus caffeinol produces robust neuroprotection after stroke in rats. Stroke 36(1):129–134. https://doi.org/10.1161/01.STR.0000149624.87661.18 CrossRefPubMedGoogle Scholar
- 25.Sughrue ME, Mocco J, Komotar RJ, Mehra A, D’Ambrosio AL, Grobelny BT, Penn DL, Connolly ES Jr (2006) An improved test of neurological dysfunction following transient focal cerebral ischemia in rats. J Neurosci Methods 151(2):83–89. https://doi.org/10.1016/j.jneumeth.2005.04.023 CrossRefPubMedGoogle Scholar
- 27.Haddad M, Beray-Berthat V, Coqueran B, Plotkine M, Marchand-Leroux C, Margaill I (2013) Combined therapy with PJ34, a poly(ADP-ribose)polymerase inhibitor, reduces tissue plasminogen activator-induced hemorrhagic transformations in cerebral ischemia in mice. Fundam Clin Pharmacol 27(4):393–401. https://doi.org/10.1111/j.1472-8206.2012.01036.x CrossRefPubMedGoogle Scholar
- 28.Zhang L, Zhang ZG, Zhang RL, Lu M, Adams J, Elliott PJ, Chopp M (2001) Postischemic (6-hour) treatment with recombinant human tissue plasminogen activator and proteasome inhibitor PS-519 reduces infarction in a rat model of embolic focal cerebral ischemia. Stroke 32(12):2926–2931. https://doi.org/10.1161/hs1201.100207 CrossRefPubMedGoogle Scholar
- 30.Moroni F, Cozzi A, Chiarugi A, Formentini L, Camaioni E, Pellegrini-Giampietro DE, Chen Y, Liang S et al (2012) Long-lasting neuroprotection and neurological improvement in stroke models with new, potent and brain permeable inhibitors of poly(ADP-ribose) polymerase. Br J Pharmacol 165(5):1487–1500. https://doi.org/10.1111/j.1476-5381.2011.01666.x CrossRefPubMedPubMedCentralGoogle Scholar
- 31.Patel MR, Bhatt A, Steffen JD, Chergui A, Murai J, Pommier Y, Pascal JM, Trombetta LD et al (2014) Discovery and structure-activity relationship of novel 2,3-dihydrobenzofuran-7-carboxamide and 2,3-dihydrobenzofuran-3(2H)-one-7-carboxamide derivatives as poly(ADP-ribose)polymerase-1 inhibitors. J Med Chem 57(13):5579–5601. https://doi.org/10.1021/jm5002502 CrossRefPubMedPubMedCentralGoogle Scholar